Application of multi-modality MRI-based radiomics in the pre-treatment prediction of RPS6K expression in hepatocellular carcinoma

[1]  R. Bernards,et al.  Evolving therapeutic landscape of advanced hepatocellular carcinoma , 2022, Nature Reviews Gastroenterology & Hepatology.

[2]  V. Mazzaferro,et al.  mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. , 2020, Annals of surgery.

[3]  P. Lampertico,et al.  Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation , 2020, Transplantation.

[4]  P. Gow,et al.  Systematic review with meta‐analysis: sirolimus‐ or everolimus‐based immunosuppression following liver transplantation for hepatocellular carcinoma , 2019, Alimentary pharmacology & therapeutics.

[5]  Huan Li,et al.  Transient Inhibition of mTORC1 Signaling Ameliorates Irradiation-Induced Liver Damage , 2019, Front. Physiol..

[6]  M. L. de la Mata,et al.  mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence , 2019, International journal of molecular sciences.

[7]  Shawn J Leroux,et al.  On the prevalence of uninformative parameters in statistical models applying model selection in applied ecology , 2018, bioRxiv.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  N. Paragios,et al.  A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. , 2018, The Lancet. Oncology.

[10]  Jie Tian,et al.  Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study , 2018, Gut.

[11]  P. Lambin,et al.  Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.

[12]  John Quackenbush,et al.  Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. , 2017, Cancer research.

[13]  D. Calvisi,et al.  A functional mammalian target of rapamycin complex 1 signaling is indispensable for c‐Myc‐driven hepatocarcinogenesis , 2017, Hepatology.

[14]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[15]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[16]  Yanqi Huang,et al.  Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. , 2016, Radiology.

[17]  Yang Yang,et al.  MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription , 2016, Hepatology.

[18]  S. Dooley,et al.  PI3K/AKT/mTOR‐dependent stabilization of oncogenic far‐upstream element binding proteins in hepatocellular carcinoma cells , 2016, Hepatology.

[19]  D. Calvisi,et al.  Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. , 2016, Journal of hepatology.

[20]  V. Mazzaferro,et al.  Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial , 2015, Transplantation.

[21]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[22]  W. Yeo,et al.  Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response , 2015, BMC Cancer.

[23]  Jeffrey W. Smith,et al.  4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N‐Ras proto‐oncogenes in mice , 2015, Hepatology.

[24]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[25]  S. Thorgeirsson,et al.  Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. , 2014, Journal of hepatology.

[26]  Ralph B D'Agostino,et al.  Misuse of DeLong test to compare AUCs for nested models , 2012, Statistics in medicine.

[27]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[28]  Zhiming Wang,et al.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma , 2010, Medical oncology.

[29]  Andrea Lampis,et al.  Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. , 2010, Journal of hepatology.

[30]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[31]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[32]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[33]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..